What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 4, 2008, Pages 691-697

  Anasetti, Claudio ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

acute leukemia; comorbidity; donor; HLA mismatch; patient; recipient; related; risk factors; transplant; unrelated

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; COMORBIDITY; CYTOGENETICS; CYTOMEGALOVIRUS; DISEASE SEVERITY; DNA POLYMORPHISM; DONOR SELECTION; GENOTYPE; HLA MATCHING; HUMAN; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PARITY; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; REVIEW; RISK FACTOR; SEROLOGY; SEX DIFFERENCE; SIBLING; THERAPY DELAY; TREATMENT INDICATION; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 56649086705     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.10.002     Document Type: Review

References (22)

1. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
2. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
3. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111 (2008) 1827-1833
4. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110 (2007) 4606-4613
5. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
6. Jones R.B. HCT outcomes: a new tool?. Blood 106 (2005) 2602-2603
7. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008) 1992-2001
8. Chang C., Storer B.E., Scott B.L., et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110 (2007) 1379-1387
9. Schwake C.J., Eapen M., Lee S.J., et al. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biology of Blood and Marrow Transplantation 11 (2005) 988-998
10. Baker K.S., Loberiza Jr. F.R., Yu H., et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. Journal of Clinical Oncology 23 (2005) 7032-7042
11. Serna D.S., Lee S.J., Zhang M.J., et al. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. Journal of Clinical Oncology 21 (2003) 3754-3760
12. Wofford J., Kemp J., Regan D., et al. Ethnically mismatched cord blood transplants in African Americans: the Saint Louis Cord Blood Bank experience. Cytotherapy 9 (2007) 660-666
13. Karabon L., Wysoczanska B., Bogunia-Kubik K., et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Human Immunology 66 (2005) 700-710
14. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. The New England Journal of Medicine 349 (2003) 2201-2210
15. Randolph S.S., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 103 (2004) 347-352
16. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99 (2002) 1971-1977
17. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 104 (2004) 1923-1930
18. Madrigal A., and Shaw B.E. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells, Molecules & Diseases 40 (2008) 40-43
19. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110 (2007) 4576-4583
20. Parham P., and McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Reviews. Immunology 3 (2003) 108-122
21. Cooley S., Miller J.S., Trachtenberg E., et al. Activating KIR (B haplotype) in unrelated donors improves disease-free survival after HLA-matched and mismatched allogeneic transplantation for acute myeloid leukemia: implications for donor selection using KIR genotyping. Blood 110 (2007) 21a [abstract 43]
22. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051